8.855

2.03% -0.225

Cullinan Therapeutics Inc (CGEM)

Overview News Price History Option Chain Financials Discussions Forecast

Cullinan Therapeutics Inc stock is traded at $8.855, with a volume of 77,764. It is down -2.03% in the last 24 hours and down -7.24% over the past month. Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Previous Close:

$9.08

Open:

$9.01

24h Volume:

77,764

Relative Volume:

0.17

Market Cap:

$522.23M

Revenue:

Net Income/Loss:

$-153.16M

P/E Ratio:

-2.3997

EPS:

-3.69

Net Cash Flow:

$-134.48M

1W Performance:

+4.53%

1M Performance:

-7.24%

6M Performance:

-50.44%

1Y Performance:

-47.61%

1-Day Range:

$8.655

$9.38

1-Week Range:

$7.95

$9.38

52-Week Range:

$7.95

$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name

Cullinan Therapeutics Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

617-410-4650

Address

ONE MAIN STREET, CAMBRIDGE

Employee

111

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

CGEM's Discussions on Twitter

Compare CGEM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEM Cullinan Therapeutics Inc	8.88	522.23M	0	-153.16M	-134.48M	-3.69
VRTX Vertex Pharmaceuticals Inc	501.29	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	683.26	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.20	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.17	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.50	26.76B	3.32B	-860.46M	-1.04B	-8.32

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-24	Initiated	UBS	Buy
May-01-24	Initiated	Stifel	Buy
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-02-21	Initiated	Evercore ISI	Outperform
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight
Feb-02-21	Initiated	SVB Leerink	Outperform
Feb-01-21	Initiated	H.C. Wainwright	Buy

View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

Mar 12, 2025

EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR

Mar 12, 2025

Mar 09, 2025

Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World

Mar 09, 2025

Mar 08, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Recommendation of “Buy” from Analysts - Defense World

Mar 08, 2025

Mar 07, 2025

Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating - TipRanks

Mar 07, 2025

Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 07, 2025

Mar 06, 2025

New York State Common Retirement Fund Buys 3,200 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 06, 2025

Cullinan Therapeutics (CGEM) to Release Quarterly Earnings on Thursday - Defense World

Mar 06, 2025

Mar 04, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at HC Wainwright - MarketBeat

Mar 04, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Announces Earnings Results - MarketBeat

Mar 04, 2025

Mar 03, 2025

Q1 Earnings Estimate for CGEM Issued By William Blair - Defense World

Mar 03, 2025

Cullinan Therapeutics’ (CGEM) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 03, 2025

Mar 01, 2025